{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T09:48:34Z","timestamp":1768816114258,"version":"3.49.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["valuehealthregionalissues.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health Regional Issues"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.vhri.2020.05.002","type":"journal-article","created":{"date-parts":[[2020,7,20]],"date-time":"2020-07-20T06:04:07Z","timestamp":1595225047000},"page":"49-54","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Cost and Effectiveness of the Treatment of Chronic Hepatitis C in Brazil: Real-World Data"],"prefix":"10.1016","volume":"23","author":[{"given":"Karin Hepp","family":"Schwambach","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mareni Rocha","family":"Farias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gi\u00e1como Balbinotto","family":"Neto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carine Raquel","family":"Blatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vhri.2020.05.002_bib1","series-title":"Hepatitis C key facts, Fact sheet no. 164","year":"2018"},{"key":"10.1016\/j.vhri.2020.05.002_bib2","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/852968","article-title":"Chronic hepatitis C: an overview of evidence on epidemiology and management from a Brazilian perspective","volume":"2015","author":"Castro","year":"2015","journal-title":"Intern J Hepatol"},{"issue":"Suppl. 1","key":"10.1016\/j.vhri.2020.05.002_bib3","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/liv.13638","article-title":"Treatment of hepatitis C: results in real life","volume":"38","author":"H\u00e9zode","year":"2018","journal-title":"Liv Intern"},{"issue":"3","key":"10.1016\/j.vhri.2020.05.002_bib4","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.cld.2017.03.012","article-title":"Economic burden of hepatitis C infection","volume":"21","author":"Stepanova","year":"2017","journal-title":"Clin Liver Dis"},{"issue":"Suppl 5","key":"10.1016\/j.vhri.2020.05.002_bib5","doi-asserted-by":"crossref","first-page":"S186","DOI":"10.1016\/j.dld.2014.09.025","article-title":"The impact of the new antiviral regimens on patient reported outcomes and health economics of patients with chronic hepatitis C","volume":"46","author":"Younossi","year":"2014","journal-title":"Dig Liver Dis"},{"issue":"Suppl 4","key":"10.1016\/j.vhri.2020.05.002_bib6","doi-asserted-by":"crossref","first-page":"3338","DOI":"10.18673\/gs.v6i4.22115","article-title":"Acesso aos medicamentos incorporados no SUS: estrat\u00e9gias para garantia da sustentabilidade econ\u00f4mica [Access to medicines incorporated in Brazilian National Health System (SUS): strategies for ensuring the economic sustainability]","volume":"6","author":"Alexandre","year":"2015","journal-title":"Revista Eletr\u00f4nica Gest\u00e3o & Sa\u00fade"},{"key":"10.1016\/j.vhri.2020.05.002_bib7","article-title":"BRASIL. Minist\u00e9rio da Sa\u00fade. Conitec. Relat\u00f3rio de recomenda\u00e7\u00e3o. Protocolo cl\u00ednico e diretrizes terap\u00eauticas para a hepatite C e coinfec\u00e7\u00f5es [Recommendation report","volume":"171","year":"2015","journal-title":"Clinical protocol and therapeutic guidelines for hepatitis C and co-infections]"},{"key":"10.1016\/j.vhri.2020.05.002_bib8","author":"Vieira","year":"2018"},{"issue":"Suppl","key":"10.1016\/j.vhri.2020.05.002_bib9","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1590\/S1413-81232008000700027","article-title":"Medicamentos e sa\u00fade p\u00fablica em tempos de AIDS: metamorfoses de uma pol\u00edtica dependente [Drugs, health policy and AIDS: changes in a dependent policy]","volume":"13","author":"Loyola","year":"2008","journal-title":"Ci\u00eanc. Sa\u00fade coletiva"},{"key":"10.1016\/j.vhri.2020.05.002_bib11","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.vhri.2012.10.001","article-title":"An estimate of the cost of hepatitis C treatment for the Brazilian health system","volume":"1","author":"Blatt","year":"2012","journal-title":"Value Health"},{"key":"10.1016\/j.vhri.2020.05.002_bib12","article-title":"BRASIL. Minist\u00e9rio da Sa\u00fade","volume":"360","year":"2018","journal-title":"Conitec. Recommendation report. Clinical protocol and therapeutic guidelines for hepatitis C and co-infections"},{"key":"10.1016\/j.vhri.2020.05.002_bib13","article-title":"BRASIL","volume":"164","year":"2015","journal-title":"Minist\u00e9rio da Sa\u00fade. Conitec. Recommendation report. Simeprevir, sofosbuvir and daclatasvir in the treatment of chronic hepatitis type C and co-infections"},{"issue":"2","key":"10.1016\/j.vhri.2020.05.002_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0172159","article-title":"Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon free DAAs in the PITER Cohort Study","volume":"12","author":"Kondili","year":"2017","journal-title":"PLoS ONE"},{"issue":"3","key":"10.1016\/j.vhri.2020.05.002_bib17","first-page":"211","article-title":"Efficacy and safety of sofosbuvir-based therapies in patients with advanced liver disease in a real-life cohort","volume":"16","author":"Kutala","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.vhri.2020.05.002_bib18","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1306218","article-title":"Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection","volume":"370","author":"Sulkowski","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.vhri.2020.05.002_bib19","doi-asserted-by":"crossref","first-page":"727","DOI":"10.5604\/01.3001.0010.2717","article-title":"Treatment of chronic HCV infection with the new direct acting antivirals (DAA): first report of a real-world experience in southern Brazil","volume":"16","author":"Sette","year":"2017","journal-title":"Ann Hepatol"},{"issue":"4","key":"10.1016\/j.vhri.2020.05.002_bib20","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.bjid.2018.06.004","article-title":"Effectiveness of chronic hepatitis C treatment with direct-acting antivirals in the Public Health System in Brazil","volume":"22","author":"Holzmann","year":"2018","journal-title":"Braz J Infect Dis"},{"issue":"3","key":"10.1016\/j.vhri.2020.05.002_bib21","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.bjid.2018.04.003","article-title":"Effectiveness and tolerability of direct-acting antivirals for chronic hepatitis C patients in a Southern state of Brazil","volume":"22","author":"Ferreira","year":"2018","journal-title":"Braz J Infect Dis"},{"issue":"Suppl. 1","key":"10.1016\/j.vhri.2020.05.002_bib22","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/liv.13293","article-title":"Hepatitis C: efficacy and safety in real life","volume":"37","author":"Flisiak","year":"2017","journal-title":"Liv Internat"},{"issue":"5","key":"10.1016\/j.vhri.2020.05.002_bib23","doi-asserted-by":"crossref","first-page":"806","DOI":"10.4254\/wjh.v7.i5.806","article-title":"Impact of all anti-hepatitis C virus therapy: a meta-analysis","volume":"7","author":"Bansall","year":"2015","journal-title":"World J of Hepatol"},{"key":"10.1016\/j.vhri.2020.05.002_bib24","first-page":"1","article-title":"B.A.R.C.O.S. (Brazilian Argentine Hepatitis C Collaborative Observational Study): Effectiveness and clinical outcomes of HCV treatment with daclatasvir and sofosbuvir with or without ribavirin","volume":"00","author":"Ridruejo","year":"2019","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.vhri.2020.05.002_bib25","article-title":"The benefits of a public pharmacist service in chronic hepatitis C treatment: The real-life results of sofosbuvir-based therapy","author":"Gomes","year":"2019","journal-title":"Res Social Adm Pharm"},{"key":"10.1016\/j.vhri.2020.05.002_bib26","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1590\/s1678-9946201860029","article-title":"Hepatitis C in Brazil: lessons learned with boceprevir and telaprevir","volume":"60","author":"Gomes","year":"2018","journal-title":"Rev Inst Med Trop"},{"issue":"1","key":"10.1016\/j.vhri.2020.05.002_bib27","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S1665-2681(19)30800-2","article-title":"Boceprevir and telaprevir for chronic genotype 1 hepatitis C virus infection. A systematic review and meta-analysis","volume":"14","author":"Manzano-Robleda Mdel","year":"2015","journal-title":"Ann Hepatol"},{"issue":"7","key":"10.1016\/j.vhri.2020.05.002_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0159976","article-title":"Outcomes and costs of treating hepatitis C patients in the era of first generation protease inhibitors - results from the PAN study","volume":"11","author":"Stahmeyer","year":"2016","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.vhri.2020.05.002_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0199941","article-title":"All-oral direct antiviral treatment for hepatitis C chronic infection in a real-life cohort: The role of cirrhosis and comorbidities in treatment response","volume":"13","author":"Miotto","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.vhri.2020.05.002_bib30","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/1471-230X-14-87","article-title":"Safety and efficacy of protease inhibitor based combination therapy in a single-center \u201creal-life\u201d cohort of 110 patients with chronic hepatitis C genotype 1 infection","volume":"14","author":"Wehmeyer","year":"2014","journal-title":"BMC Gastroenterol"},{"issue":"22","key":"10.1016\/j.vhri.2020.05.002_bib31","doi-asserted-by":"crossref","first-page":"949","DOI":"10.4254\/wjh.v8.i22.949","article-title":"Boceprevir or telaprevir in hepatitis C virus chronic infection: the Italian real life experience","volume":"8","author":"Ascione","year":"2016","journal-title":"World J Hepatol"},{"issue":"11","key":"10.1016\/j.vhri.2020.05.002_bib32","doi-asserted-by":"crossref","first-page":"e305","DOI":"10.1371\/journal.pmed.0040305","article-title":"Evolution of antiretroviral drug costs in Brazil in the context of free and universal access to AIDS treatment","volume":"4","author":"Nunn","year":"2007","journal-title":"PLoS Med"},{"key":"10.1016\/j.vhri.2020.05.002_bib33","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1186\/s12889-016-3784-4","article-title":"The Brazilian comprehensive response to hepatitis C: from strategic thinking to access to interferon-free therapy","volume":"16","author":"Mesquita","year":"2016","journal-title":"BMC Public Health"},{"issue":"4","key":"10.1016\/j.vhri.2020.05.002_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0174616","article-title":"Trends in medicines procurement by the Brazilian federal government from 2006 to 2013","volume":"12","author":"Chama Borges Luz","year":"2017","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.vhri.2020.05.002_bib35","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1590\/1413-81232017228.05602017","article-title":"Public procurement of hepatitis C medicines in Brazil from 2005 to 2015","volume":"22","author":"Chaves","year":"2017","journal-title":"Ci\u00eanc sa\u00fade coletiva"},{"key":"10.1016\/j.vhri.2020.05.002_bib36","doi-asserted-by":"crossref","first-page":"e676","DOI":"10.1016\/S2214-109X(15)00156-4","article-title":"Disparity in market prices for hepatitis C virus direct-acting drugs","volume":"3","author":"Andrieux-Meyer","year":"2015","journal-title":"Lancet Glob Health"},{"issue":"2","key":"10.1016\/j.vhri.2020.05.002_bib37","article-title":"Exceptional circumstance drug dispensing: history and expenditures of the Brazilian Ministry of Health","volume":"45","author":"Carias","year":"2011","journal-title":"Rev Sa\u00fade P\u00fablica"},{"issue":"5","key":"10.1016\/j.vhri.2020.05.002_bib38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002032","article-title":"Prices, costs, and affordability of new medicines for hepatitis C in 30 countries: an economic analysis","volume":"13","author":"Iyengar","year":"2016","journal-title":"PLoS Med"},{"key":"10.1016\/j.vhri.2020.05.002_bib39","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s12876-017-0676-8","article-title":"Micro-costing analysis of guideline-based treatment by direct-acting agents: the real life case of hepatitis C management in Brazil","volume":"17","author":"Perazzo","year":"2017","journal-title":"BMC Gastro"},{"issue":"1","key":"10.1016\/j.vhri.2020.05.002_bib40","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12992-017-0297-6","article-title":"Access to medicines and hepatitis C in Africa: can tiered pricing and voluntary licensing assure universal access, health equity and fairness?","volume":"13","author":"Assefa","year":"2017","journal-title":"Global Health"},{"issue":"Suppl 1","key":"10.1016\/j.vhri.2020.05.002_bib41","article-title":"Role of generics in treatment of hepatitis C infection","volume":"28","author":"Umar","year":"2016","journal-title":"J\u00a0Ayub Med Coll"},{"issue":"7","key":"10.1016\/j.vhri.2020.05.002_bib42","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1056\/NEJMp1812959","article-title":"Brazil's fight against hepatitis C - universalism, local production, and patents","volume":"380","author":"da Fonseca","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.vhri.2020.05.002_bib43","first-page":"72","article-title":"Secretaria de Vigil\u00e2ncia em Sa\u00fade, Departamento de Vigil\u00e2ncia, Preven\u00e7\u00e3o e Controle das IST, do HIV\/Aids e das Hepatites Virais (DIAHV). Epidemiological Bulletin-Viral Hepatitis","volume":"1","author":"BRASIL","year":"2018","journal-title":"Ano VI"}],"container-title":["Value in Health Regional Issues"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109920300388?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109920300388?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T20:12:46Z","timestamp":1761941566000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212109920300388"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":40,"alternative-id":["S2212109920300388"],"URL":"https:\/\/doi.org\/10.1016\/j.vhri.2020.05.002","relation":{},"ISSN":["2212-1099"],"issn-type":[{"value":"2212-1099","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost and Effectiveness of the Treatment of Chronic Hepatitis C in Brazil: Real-World Data","name":"articletitle","label":"Article Title"},{"value":"Value in Health Regional Issues","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vhri.2020.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 ISPOR--The professional society for health economics and outcomes research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}